Interferon-γ and cancer immunoediting

[1]  R. Schreiber,et al.  The immunobiology of cancer immunosurveillance and immunoediting. , 2004, Immunity.

[2]  R. Schreiber,et al.  The three Es of cancer immunoediting. , 2004, Annual review of immunology.

[3]  G. Forni,et al.  α-Galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[4]  F. Alt,et al.  Deficiencies of GM-CSF and Interferon γ Link Inflammation and Cancer , 2003, The Journal of experimental medicine.

[5]  R. MacKie,et al.  Fatal melanoma transferred in a donated kidney 16 years after melanoma surgery. , 2003, The New England journal of medicine.

[6]  George Coukos,et al.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. , 2003, The New England journal of medicine.

[7]  R. Schreiber,et al.  Cancer immunoediting: from immunosurveillance to tumor escape , 2002, Nature Immunology.

[8]  J. Trapani,et al.  Suppression of Lymphoma and Epithelial Malignancies Effected by Interferon γ , 2002, The Journal of experimental medicine.

[9]  Lloyd J. Old,et al.  The roles of IFNγ in protection against tumor development and cancer immunoediting , 2002 .

[10]  M. Smyth,et al.  Increased Susceptibility to Tumor Initiation and Metastasis in TNF-Related Apoptosis-Inducing Ligand-Deficient Mice1 , 2002, The Journal of Immunology.

[11]  M. Smyth,et al.  Critical Role for Tumor Necrosis Factor–related Apoptosis-inducing Ligand in Immune Surveillance Against Tumor Development , 2002, The Journal of experimental medicine.

[12]  Julia M. Lewis,et al.  Regulation of Cutaneous Malignancy by γδ T Cells , 2001, Science.

[13]  P. Schlag,et al.  Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. , 2001, Cancer research.

[14]  R. Schreiber,et al.  IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity , 2001, Nature.

[15]  J. Trapani,et al.  Perforin-Mediated Cytotoxicity Is Critical for Surveillance of Spontaneous Lymphoma , 2000, The Journal of experimental medicine.

[16]  A. Scott,et al.  Therapeutic efficacy of anti-Lewis(y) humanized 3S193 radioimmunotherapy in a breast cancer model: enhanced activity when combined with taxol chemotherapy. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  J. Trapani,et al.  Differential Tumor Surveillance by Natural Killer (Nk) and Nkt Cells , 2000, The Journal of experimental medicine.

[18]  S. Akira,et al.  Interleukin-10 Receptor Signaling through the JAK-STAT Pathway , 1999, The Journal of Biological Chemistry.

[19]  Loise M. Francisco,et al.  Tumor-specific killer cells in paraneoplastic cerebellar degeneration , 1998, Nature Medicine.

[20]  P. Hogan,et al.  Advanced donor-origin melanoma in a renal transplant recipient: immunotherapy, cure, and retransplantation. , 1998, Transplantation.

[21]  H Nagura,et al.  CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. , 1998, Cancer research.

[22]  R. Schreiber,et al.  Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice , 1998 .

[23]  P. Hersey,et al.  Remission of transplanted melanoma--clinical course and tumour cell characterisation. , 1997, Clinical transplantation.

[24]  R. Zinkernagel,et al.  Decreased tumor surveillance in perforin-deficient mice , 1996, The Journal of experimental medicine.

[25]  J. Darnell,et al.  Stat3 Recruitment by Two Distinct Ligand-induced, Tyrosine-phosphorylated Docking Sites in the Interleukin-10 Receptor Intracellular Domain* , 1996, The Journal of Biological Chemistry.

[26]  L. Old,et al.  Effect of interleukin 12 on tumor induction by 3-methylcholanthrene. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[27]  M. Weber,et al.  Atrial Natriuretic Peptide Inhibits Mitogen-activated Protein Kinase through the Clearance Receptor , 1996, The Journal of Biological Chemistry.

[28]  R. Darnell.  Onconeural antigens and the paraneoplastic neurologic disorders: at the intersection of cancer, immunity, and the brain. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[29]  Natale Cascinelli,et al.  Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma , 1996, Cancer.

[30]  R. Schreiber,et al.  Targeted Disruption of the Stat1 Gene in Mice Reveals Unexpected Physiologic Specificity in the JAK–STAT Signaling Pathway , 1996, Cell.

[31]  I. Penn.  Malignant melanoma in organ allograft recipients. , 1996, Transplantation.

[32]  I. Penn,et al.  Sarcomas in organ allograft recipients. , 1995, Transplantation.

[33]  R. Schreiber,et al.  Tissue-specific targeting of cytokine unresponsiveness in transgenic mice. , 1995, Immunity.

[34]  Eero Pukkala,et al.  Cancer risk after renal transplantation in the nordic countries, 1964–1986 , 1995, International journal of cancer.

[35]  R. Schreiber,et al.  Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. , 1994, Immunity.

[36]  M. Farrar,et al.  Inhibition of cellular responsiveness to interferon-gamma (IFN gamma) induced by overexpression of inactive forms of the IFN gamma receptor. , 1993, Journal of Biological Chemistry.

[37]  R. Zinkernagel,et al.  Immune response in mice that lack the interferon-gamma receptor. , 1993, Science.

[38]  V. Stewart,et al.  RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement , 1992, Cell.

[39]  J. Uhr,et al.  Cancer dormancy: studies of the murine BCL1 lymphoma. , 1991, Cancer research.

[40]  A. Halpern,et al.  Model predicting survival in stage I melanoma based on tumor progression. , 1989, Journal of the National Cancer Institute.

[41]  L. Sherman,et al.  The composition of the T cell receptor repertoire in nude mice. , 1987, Journal of immunology.

[42]  L. Old,et al.  T-cell-mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin 2-dependent T-cell cultures. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[43]  S. Ikehara,et al.  Functional T cells in athymic nude mice. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[44]  T. Hünig.  T-cell function and specificity in athymic mice , 1983 .

[45]  L. Thomas.  THE YALE JOURNAL OF BIOLOGY AND MEDICINE 55 (1982), 329-333 On Immunosurveillance in Human Cancer , 1982 .

[46]  O. Stutman.  Tumor Development after 3-Methylcholanthrene in Immunologically Deficient Athymic-Nude Mice , 1974, Science.

[47]  R. Schreiber,et al.  Response to 'A cancer immunosurveillance controversy' , 2004, Nature Immunology.

[48]  R. Schreiber,et al.  IFNγ Receptor-STAT1 Signaling and Cancer Immunoediting , 2003 .

[49]  Takuma Hayashi,et al.  Development of spontaneous uterine tumors in low molecular mass polypeptide-2 knockout mice. , 2002, Cancer research.

[50]  M. Smyth,et al.  Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. , 2001, Blood.

[51]  M Aguet,et al.  The IFN gamma receptor: a paradigm for cytokine receptor signaling. , 1997, Annual review of immunology.

[52]  M. Mihm,et al.  Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. , 1996, Laboratory investigation; a journal of technical methods and pathology.

[53]  K. Weinhold,et al.  The tumor dormant state. , 1981, Advances in cancer research.

[54]  R. Herberman,et al.  Natural cell-mediated immunity. , 1978, Advances in cancer research.

[55]  F. Burnet.  The concept of immunological surveillance. , 1970, Progress in experimental tumor research.